赵艳秋教授解读TOP研究：EGFR敏感突变（Ex19del/L858R）-TP53共突变晚期NSCLC一线治疗高级别循证证据公布_腾讯新闻
前言当前，表皮生长因子受体（EGFR）敏感突变（Ex19del/L858R）晚期非...
Structural classification of EGFR mutations and its association with TKI efficacy against compound and co-mutations in a Chinese NSCLC cohort: a single-center retrospective analysis
AbstractBackground Epidermal growth factor receptor(EGFR)mutations have been classified into four distinct subgroups based on the characteristics of the kinase domain and their sensitivity to tyrosine kinase inhibitors (TKIs).However, literature regarding the distribution and biological features of these structural subtypes among...
A U‐Shaped Association: The First‐Year eGFR Slope and Mortality Risk in Multiple Myeloma
Cancer MedicineVolume 15, Issue 9 e72168 RESEARCH ARTICLEOpen Access A U-Shaped Association: The First-Year eGFR Slope and Mortality Risk in Multiple Myeloma Lian Li, Lian Li Department of Hematology/Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China Department of...
A U‐Shaped Association: The First‐Year eGFR Slope and Mortality Risk in Multiple Myeloma
Background Renal impairment (RI) increases mortality risk in multiple myeloma (MM), yet RI represents a relatively late stage of kidney dysfunction. Whether early indicators of renal dysfunction, su 1 Introduction Multiple myeloma (MM) is incurable and the second most prevalent...
Practical Management in EGFR-Mutant NSCLC: Infusion Logistics, Skin Toxicity, and Quality of Life
Practical Management in EGFR-Mutant NSCLC: Infusion Logistics, Skin Toxicity, and Quality of Life Dr. Patel asks how supportive care demands, quality of life, and financial and time toxicities shape shared decision-making in frontline EGFR-mutated non-small cell lung cancer (NSCLC), and...
Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma
BackgroundThird-generation epidermal growth factor receptor tyrosine kinase inhibitor osimertinib serves as the gold standard therapy for treating NSCLC pati Abstract Background: Third-generation epidermal growth factor receptor tyrosine kinase inhibitor osimertinib serves as the gold standard therapy for treating NSCLC patients...
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a...
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy Key PointsInterested in HUTCHMED (China) Limited Sponsored ADR? Here are five stocks we like better.HUTCHMED signed a deal with GSK worth up to approximately $1.3 billion for ex-China...
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
- Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 - - HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT /...